Many patients with major depressive disorder (MDD) do not respond to traditional antidepressant medication or only respond partially. As a result, augmentation therapy with atypical antipsychotic medications is required in many patients, boosting antidepressant effect and extending partial remission. In patients with MDD, this trial compared augmentation therapy with ziprasidone and quetiapine to escitalopram. A prospective, open-label, randomised, comparative clinical trial was conducted. Part-I of the study comprised adult patients who fulfilled the DSM-5 criteria for MDD and had a HAM-D score of 15 or more on the 17-item version. The critical exclusion criteria were MDD with psychotic symptoms and bipolar illness. After 6 weeks of escitalopram (20 mg per day) treatment, eligible patients who had an inadequate response to treatment (Part-II of the study) were randomly assigned to one of two treatment groups: quetiapine 200 mg once daily or ziprasidone 20 mg twice daily orally for 6 weeks. Efficacy was measured using BDI scores at 2, 4, and 6 weeks during the clinical trial. Adverse drug reactions (ADRs) were minimal in both groups, and none of the research participants required therapy cessation. The addition of quetiapine and ziprasidone to antidepressant therapy was found to be safe and effective in this trial.
Author(s) Details:
Sahil Sharma,
Department of Pharmacology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India.
Jarnail Singh Braich,
Department of Pharmacology, Pt. BD Sharma PGIMS, Rohtak, Haryana, India.
Hitesh Khurana,
State Institute of Mental Health/Department of Psychiatry, Pt. BD Sharma
PGIMS, Rohtak, Haryana, India.
Please see the link here: https://stm.bookpi.org/CAPRD-V9/article/view/5964
No comments:
Post a Comment